You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Litigation Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ARBUTUS PHARMA CORP. v. PFIZER INC.
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .

Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2023-04-04 1 Complaint November 29, 2016 (the “’651 Patent”). b. U.S. Patent No. 8,492,359, “Lipid Formulations for…infringement of the ’651 Patent. COUNT 2: INFRINGEMENT OF U.S. PATENT NO. 8,492,359 80. … acid-based medicines: U.S. Patent Nos. 9,504,651 (Exhibit A); 8,492,359 (Exhibit B); 11,141,378 (Exhibit… them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid…’320 Patent under 35 U.S.C. § 271(a) by using the patented apparatus covered by the ’320 Patent to make External link to document
2024-07-11 101 Redacted Document 15, 2008 provisional application: U.S. Patent Nos.: 8,058,069, 8,822,668, and 9,364,435. Case 3:23-cv…success of Comirnaty®, asserting five patents (across two patent families that date back to 2002 and …Comirnaty® infringes those asserted patents. The asserted patents, however, do not claim the specific …attempt by Plaintiffs to leverage the patents-in-suit (or patent family members thereof) into an unearned… of the same patents-in-suit, as well as three additional family members to the patents-in-suit.2 Each External link to document
2024-07-11 102 Redacted Document a single excerpt of a claim from U.S. Patent No. 8,492,359 asserted in this case, both excerpts referring…Plaintiffs emphasize each patent’s generic reference to mRNA, and each patent claim’s recitation of “an…Alnylam) is asserting its own patents that are unrelated to the patents in this case. Plaintiffs’ request…this case patents purporting to relate to the discovery of a new lipid ingredient. The patents at issue…claim from just one of the six patents asserted in Alnylam (U.S. Patent 11,382,979), comparing it to a External link to document
2023-07-10 17 Answer to Complaint vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. …Office issued the ’651 Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims…manufacturing them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid External link to document
2023-08-14 29 Answer to Counterclaim vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, … Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. ANSWER…the Asserted Patents, and unenforceability of the ’378 Patent, ’320 Patent, and ’098 Patent. Plaintiffs…was issued the ’359 Patent, the ’668 Patent, and the ’435 Patent. Those patents speak for themselves… “’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims External link to document
2024-07-11 99 Redacted Document of U.S. Patent No. 8,492,359, one of the patents asserted here. For example, the ’979 patent claims, …of U.S. Patent No. 11,382,979, among others. Ex. G at 8-9, 15-18. And the claims of that patent overlap…documents that Pfizer or BioNTech produced in another patent infringement case involving Pfizer’s COVID-19 vaccine…irrelevant because Alnylam “involves different patents.” Ex. B at 6. That is mistaken for multiple independent… 35-65 mol % of a cationic lipid,” and the ’359 patent claims “[a] nucleic acid-lipid particle comprising External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.